Ultragenyx Pharmaceutical Inc.
DTX301
Ornithine Transcarbamylase, or OTC, deficiency
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for DTX301 in Ornithine Transcarbamylase, or OTC, deficiency are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Data are expected in the first half of 2027.”